Comparative effectiveness of biologic therapy in the Psoriasis Longitudinal Assessment and Registry (P.S.O.L.A.R.) Study - 21/04/16
Bruce Strober, MD, University of Connecticut Health Center and Probity Medical Research, Farmington, CT, United States; Robert Bissonnette, MD, Innovaderm Research, Inc, Montréal, Quebec, United States; David Fiorentino, MD, Stanford University, Redwood City, CA, United States; Alexa B. Kimball, MD, Harvard Medical School, Boston, MA, United States; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai, New York, NY, United States; Luigi Naldi, MD, Centro Studi GISED, Azienda Ospedaliera Papa Giovanni XIII, Bergamo, Italy; Neil Shear, MD, University of Toronto, Toronto, Ontario, Canada; Kavitha Goyal, MD, Janssen Scientific Affairs, LLC, Horsham, PA, United States; Langholff Wayne, PhD, Janssen Research and Development, LLC, Horsham, PA, United States; Steve Fakharzadeh, MD, Janssen Scientific Affairs, LLC, Horsham, PA, United States
Le texte complet de cet article est disponible en PDF.| Supported 100% by Janssen Scientific Affairs, LLC. |
Vol 74 - N° 5S1
P. AB240 - mai 2016 Retour au numéro
Article précédent
- Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for nonmedical reasons in psoriatic disease patients
- Comparison of a selective IL-23p19 inhibitor (BI 655066) with ustekinumab in patients with moderate-to-severe plaque psoriasis: Analysis of scalp, palmoplantar, and nail psoriasis subgroups
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?